NIH-funded research U01 cooperative agreement

Monitoring COVID-19 immune responses in patients with blood cancers

Official title: Immuno-Serological Assays for Monitoring COVID19 in Patients with Hematologic Malignancies

Funded at Yale University · NIH-11160167 · Data updated 2026-11-12

This study looks at how well COVID-19 vaccines work in people with blood cancers or autoimmune diseases compared to healthy individuals, using skin samples and blood tests to better understand their immune responses, which could lead to more personalized treatments and vaccines for those with these conditions.

More Hematologic Malignancies research and trials

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionYale University
NIH-funded
Lab location1 site (New Haven, United States)
Project startSeptember 30, 2020
Project endAugust 31, 2025
Funding year2024
Award (this year)$107,220
NIH project number3U01CA260507-02S3
Project IDNIH-11160167 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals with hematologic malignancies or autoimmune diseases who have received a COVID-19 vaccine.

Less likely to help

Patients without hematologic malignancies or autoimmune diseases may not benefit from this research.

What this research studies

This research investigates how the immune system responds to COVID-19 vaccines in patients with hematologic malignancies compared to healthy individuals. It utilizes advanced imaging techniques to analyze skin biopsy samples from both groups, focusing on the presence of the SARS-CoV-2 Spike protein and other immune markers. By correlating these findings with blood tests, the study aims to understand the unique immune responses in patients with blood disorders or autoimmune diseases. This could help tailor COVID-19 treatments and vaccinations for these vulnerable populations.

Why it matters

Potential benefit: If successful, this research could lead to improved COVID-19 vaccination strategies and treatments for patients with hematologic malignancies.

How similar studies have gone: Other research has shown promising results in understanding immune responses to vaccines in similar patient populations, indicating that this approach has potential for success.

Where this research is happening

  • Yale University
    New Haven, United States
    Active

Researchers

  • Principal investigator: Fan, Rong — Yale University
  • Study coordinator: Fan, Rong

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.